Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors. Issue 1 (23rd September 2020)

• Record Type: Journal Article
• Authors: Rafia, Chirine; Harly, Christelle; Scotet, Emmanuel
• Is Part Of: Immunological reviews. Volume 298:Issue 1(2020)
• Page Start: 117
• Page End: 133
• Publication Date: 2020-09-23
• Subjects: ACT -- CAR T cells -- CRISPR -- engineering -- solid tumor -- Vγ9Vδ2 T cells; Immunology -- Periodicals; Transplantation of organs, tissues, etc -- Periodicals; 616.079
• DOI: 10.1111/imr.12920
• Languages: English
• ISSNs: 0105-2896

Abstract

Abstract: Despite recent significant progress in cancer immunotherapies based on adoptive cell transfer(s)(ACT), the eradication of cancers still represents a major clinical challenge. In particular, the efficacy of current ACT‐based therapies against solid tumors is dramatically reduced by physical barriers that prevent tumor infiltration of adoptively transferred effectors, and the tumor environment that suppress their anti‐tumor functions. Novel immunotherapeutic strategies are thus needed to circumvent these issues. Human peripheral blood Vγ9Vδ2 T cells, a non‐alloreactive innate‐like T lymphocyte subset, recently proved to be a promising anti‐tumor effector subset for ACT‐based immunotherapies. Furthermore, new cell engineering tools that leverage the potential of CRISPR/Cas technology open astounding opportunities to optimize their anti‐tumor effector functions. In this review, we present the current ACT strategies based on engineered T cells and their limitations. We then discuss the potential of engineered Vγ9Vδ2 T cell to overcome these limitations and improve ACT‐based cancer immunotherapies.